30-04-2020

Information for healthcare professionals

National Institute for Health and Care Excellence (NICE) (Reino Unido) – COVID-19 Rapid guidelines and evidence summaries

Cuando comenzó la pandemia de COVID-19, el National Institute for Health and Care Excellence (NICE) de Reino Unido inició la publicación de una serie de Rapid guidelines and evidence summaries.

Incluimos en este apartado los enlaces a estas guidelines.

Enlaces comprobados el 27 de abril de 2020

 

NICE - COVID-19 Rapid guidelines and evidence summaries

 

Pueden consultarse todos los documentos publicados en el siguiente enlace:

https://www.nice.org.uk/guidance/conditions-and-diseases/infections/covid19/products?Status=Published

 

Esta página va actualizándose a medida que se crean nuevos documentos o se actualizan algunos de los ya existentes.

 

1.       COVID-19 rapid guideline: critical care in adults (NG159)

Product type: Guidance

Programme: NICE guideline

Last updated: 24 April 2020

Published date: 20 March 2020

 

2.       COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

Product type: Guidance

Programme: NICE guideline

Last updated: 24 April 2020

Published date: 3 April 2020

 

3.       COVID-19 rapid guideline: acute myocardial injury (NG171)

Product type: Guidance

Programme: NICE guideline

Published date: 23 April 2020

 

4.       COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

Product type: Guidance

Programme: NICE guideline

Published date: 23 April 2020

 

5.       COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

Product type: Guidance

Programme: NICE guideline

Last updated: 23 April 2020

Published date: 3 April 2020

 

6.       COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

Product type: Guidance

Programme: NICE guideline

Last updated: 22 April 2020

Published date: 3 April 2020

 

7.       COVID-19 rapid guideline: cystic fibrosis (NG170)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

 

8.       COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

 

9.       COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

 

10.   COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

Product type: Guidance

Programme: NICE guideline

Last updated: 9 April 2020

Published date: 20 March 2020

 

11.   COVID-19 rapid guideline: severe asthma (NG166)

Product type: Guidance

Programme: NICE guideline

Published date: 3 April 2020

 

12.   COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

Product type: Guidance

Programme: NICE guideline

Published date: 1 April 2020

 

13.   COVID-19 rapid guideline: delivery of radiotherapy (NG162)

Product type: Guidance

Programme: NICE guideline

Published date: 28 March 2020

 

14.   COVID-19 rapid guideline: dialysis service delivery (NG160)

Product type: Guidance

Programme: NICE guideline

Published date: 20 March 2020

 

15.   COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

Product type: Advice

Programme: Evidence summary

Published date: 14 April 2020

 

16.   Lifelight First for monitoring vital signs (MIB213)

Product type: Advice

Programme: Medtech innovation briefing

Published date: 8 April 2020

 

17.   myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

Product type: Advice

Programme: Medtech innovation briefing

Published date: 1 April 2020

 

 

 

 

 

MA-OTH-ES-0008-1

04/ 2020